Lactobacillus casei modulates inflammatory cytokines and metabolites during tuberculosis treatment: A post hoc randomized controlled trial.

IF 1.3 4区 医学 Q4 NUTRITION & DIETETICS Asia Pacific journal of clinical nutrition Pub Date : 2022-03-01 DOI:10.6133/apjcn.202203_31(1).0008
Lan Jiang, Jinyu Wang, Lei Xu, Jing Cai, Shanliang Zhao, A. Ma
{"title":"Lactobacillus casei modulates inflammatory cytokines and metabolites during tuberculosis treatment: A post hoc randomized controlled trial.","authors":"Lan Jiang, Jinyu Wang, Lei Xu, Jing Cai, Shanliang Zhao, A. Ma","doi":"10.6133/apjcn.202203_31(1).0008","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND OBJECTIVES\nInflammatory cytokines and metabolic abnormalities are common in patients with tuberculosis. Observational studies have indicated that probiotics modulate inflammatory cytokines and metabolites; however, clinical evidence of the effect of probiotics on patients with tuberculosis is lacking. This study investigated the effects of Lactobacillus casei on inflammatory cytokines and metabolites during tuberculosis treatment.\n\n\nMETHODS AND STUDY DESIGN\nA randomized controlled trial was conducted. A total of 47 inpatients were included and randomly assigned to receive standard antituberculosis therapy only (control group) or that treatment together with 1 × 1010 colony-forming units per day of Lactobacillus casei (low-dose group) or 2 × 1010 colony-forming units per day of Lactobacillus casei (high-dose group) for 4 weeks of intensive treatment during hospitalization. Plasma samples were analyzed for inflammatory cytokines and metabolomics with ELISA kits and ultrahigh performance liquid chromatography quadrupole time-of-flight mass spectrometry.\n\n\nRESULTS\nDaily Lactobacillus casei supplementation of up to 2 × 1010 colony-forming units significantly lowered the concentrations of tumor necrosis factor-α, interleukin-6, interleukin-10, and interleukin-12 (p=0.007, p=0.042, p=0.002, p<0.001, respectively) in patients with tuberculosis. Compared with the control and low-dose groups, the plasma metabolites of phosphatidylserine, maresin 1, phosphatidylcholine, L-saccharopine, and pyridoxamine were significantly upregulated, and N-acetylmethionine, L-tryptophan, phosphatidylethanolamine, and phenylalanine were downregulated in the high-dose group. Strong correlations were observed between metabolites and inflammatory cytokines.\n\n\nCONCLUSIONS\nLactobacillus casei supplementation during the intensive phase of tuberculosis treatment can significantly modulate inflammatory cytokines and metabolites. Decreased inflammatory cytokines may be related to metabolite changes.","PeriodicalId":8486,"journal":{"name":"Asia Pacific journal of clinical nutrition","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific journal of clinical nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6133/apjcn.202203_31(1).0008","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 9

Abstract

BACKGROUND AND OBJECTIVES Inflammatory cytokines and metabolic abnormalities are common in patients with tuberculosis. Observational studies have indicated that probiotics modulate inflammatory cytokines and metabolites; however, clinical evidence of the effect of probiotics on patients with tuberculosis is lacking. This study investigated the effects of Lactobacillus casei on inflammatory cytokines and metabolites during tuberculosis treatment. METHODS AND STUDY DESIGN A randomized controlled trial was conducted. A total of 47 inpatients were included and randomly assigned to receive standard antituberculosis therapy only (control group) or that treatment together with 1 × 1010 colony-forming units per day of Lactobacillus casei (low-dose group) or 2 × 1010 colony-forming units per day of Lactobacillus casei (high-dose group) for 4 weeks of intensive treatment during hospitalization. Plasma samples were analyzed for inflammatory cytokines and metabolomics with ELISA kits and ultrahigh performance liquid chromatography quadrupole time-of-flight mass spectrometry. RESULTS Daily Lactobacillus casei supplementation of up to 2 × 1010 colony-forming units significantly lowered the concentrations of tumor necrosis factor-α, interleukin-6, interleukin-10, and interleukin-12 (p=0.007, p=0.042, p=0.002, p<0.001, respectively) in patients with tuberculosis. Compared with the control and low-dose groups, the plasma metabolites of phosphatidylserine, maresin 1, phosphatidylcholine, L-saccharopine, and pyridoxamine were significantly upregulated, and N-acetylmethionine, L-tryptophan, phosphatidylethanolamine, and phenylalanine were downregulated in the high-dose group. Strong correlations were observed between metabolites and inflammatory cytokines. CONCLUSIONS Lactobacillus casei supplementation during the intensive phase of tuberculosis treatment can significantly modulate inflammatory cytokines and metabolites. Decreased inflammatory cytokines may be related to metabolite changes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在结核病治疗期间,干酪乳杆菌调节炎症细胞因子和代谢物:一项事后随机对照试验。
背景与目的炎症细胞因子和代谢异常在肺结核患者中很常见。观察研究表明,益生菌调节炎性细胞因子和代谢产物;然而,益生菌对肺结核患者疗效的临床证据尚缺乏。本研究探讨了干酪乳杆菌在结核病治疗过程中对炎性细胞因子和代谢产物的影响。方法与研究设计采用随机对照试验。共有47名住院患者被纳入并随机分配接受标准抗结核治疗(对照组),或在住院期间接受每天1×1010个菌落形成单位的干酪乳杆菌(低剂量组)或每天2×1010个集落形成单位的酪蛋白乳杆菌(高剂量组)的强化治疗4周。用ELISA试剂盒和超高效液相色谱-四极飞行时间质谱法分析血浆样品的炎性细胞因子和代谢组学。结果每日补充2×1010菌落形成单位的干酪乳杆菌可显著降低肺结核患者的肿瘤坏死因子-α、白细胞介素-6、白细胞白细胞介蛋白-10和白细胞介因子-12的浓度(分别为p=0.007、p=0.042、p=0.002、p<0.001)。与对照组和低剂量组相比,高剂量组的磷脂酰丝氨酸、马雷蛋白1、磷脂酰胆碱、L-糖固酶和吡哆胺的血浆代谢产物显著上调,N-乙酰甲硫氨酸、L-色氨酸、磷脂酰乙醇胺和苯丙氨酸下调。代谢产物和炎性细胞因子之间存在很强的相关性。结论在结核病强化治疗期间补充干酪乳杆菌可显著调节炎性细胞因子和代谢产物。炎性细胞因子的减少可能与代谢产物的变化有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.50
自引率
7.70%
发文量
58
审稿时长
6-12 weeks
期刊介绍: The aims of the Asia Pacific Journal of Clinical Nutrition (APJCN) are to publish high quality clinical nutrition relevant research findings which can build the capacity of clinical nutritionists in the region and enhance the practice of human nutrition and related disciplines for health promotion and disease prevention. APJCN will publish original research reports, reviews, short communications and case reports. News, book reviews and other items will also be included. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer-reviewed by at least two anonymous reviewers and the Editor. The Editorial Board reserves the right to refuse any material for publication and advises that authors should retain copies of submitted manuscripts and correspondence as material cannot be returned. Final acceptance or rejection rests with the Editorial Board
期刊最新文献
Nutritional therapy among adult patients with severe burns: A retrospective observational study. Resting energy expenditure in patients with liver cirrhosis: Indirect calorimetry vs. predictive equations. Risk or associated factors of wasting among under-five children in Bangladesh: A systematic review. The impact of tea consumption on the risk of depression: A Mendelian randomization and Bayesian weighting algorithm study. A nomogram for predicting nutritional risk before gastric cancer surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1